The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...

GlaxoSmithKline Pharmaceuticals on Friday said its net profit increased over five-fold to Rs 229 crore for the third quarter ended December 31, 2024.

GlaxoSmithKline Pharmaceuticals reports a five-fold jump in net profit for the third quarter ending December 31, 2024, ...

GlaxoSmithKline Pharmaceuticals reported a significant increase in net profit to Rs 229 crore for the third quarter ending ...

GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...

In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...

GSK Pharma reported strong Q3 performance with revenue up 18% and EBITDA rising 34%. Key brands, including Augmentin and ...